Navigation Links
Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist
Date:2/3/2009

FREISING-WEIHENSTEPHAN, Germany, February 3 /PRNewswire/ -- Pieris AG, a biopharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, reports today that it has made significant progress in the development of its Anticalin(R) candidate PRS-050, a potent VEGF antagonist with broad therapeutic applicability.

Having successfully demonstrated the mode of action of PRS-050 in vitro and in vivo, Pieris has now validated the efficacy of the Anticalin(R) product candidate in several preclinical models. Amongst those tested, DCE-MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging) has been established and validated to monitor immediate treatment effects in the upcoming Phase I clinical trial. Production process parameters for GMP manufacture of PRS-050 have also been clearly defined. Initial toxicology results have shown that PRS-050 is very well tolerated.

Progress in the PRS-050 program demonstrates that Pieris has fulfilled critical speed and capacity goals in producing Anticalins(R) as clinical product candidates. Discovery programs can be advanced from lead candidate to GMP production in less than twelve months. Furthermore, several grams per liter production of Anticalins(R) in Wacker Biotech's proprietary bacterial secretion system ESETEC(R) supports broad therapeutic application of the Anticalin(R) technology.

In light of the progress in its lead proprietary program, the Company also announced the expansion of its Management Team with the appointment of Dr Kristian Jensen as Chief Operating Officer. Dr Angelika Stern will henceforth be fully dedicated to management of the PRS-050 program in her new function as Head of Project Management Angiogenesis.

Kristian Jensen joins Pieris from Merck Serono, where he spent almost three years establishing and managing its phage display antibody facility in Geneva, Switzerland. Prior to Merck
'/>"/>

SOURCE Pieris AG
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050
2. MannKind Reports Successful Completion of Device Bioequivalence Trial
3. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
4. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
5. Pharmasset Reports Fiscal Year End 2008 Financial Results
6. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
7. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
8. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
9. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
10. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
11. GEN Reports on the Trend Toward Predictive Toxicogenomics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Wash. , May 21, 2013  IsoRay, Inc. ... today that it has entered into an exclusive international ... IsoRay,s complete product line in Greece ... in seed brachytherapy and medical radioisotope applications for brain ... and gynecologic ("gyn") cancer. IASIS Medical ...
(Date:5/21/2013)... Calif. , May 21, 2013 ... and manufacture of wireless personal healthcare products and ... its reach, announcing the release of two new ... blood pressure monitors and scales: the Wireless Pulse ... (Photo: http://photos.prnewswire.com/prnh/20130521/SF17618 ) ...
(Date:5/21/2013)...  The North Shore-LIJ Health System is expanding a ... at North Shore University Hospital in Manhasset, ... at Forest Hills (NY) Hospital. ... new pilot program strengthens patient safety by providing hospitals ... first time in the US that remote video auditing ...
Breaking Medicine Technology:IsoRay Announces A New International Distributor For Greece 2IsoRay Announces A New International Distributor For Greece 3iHealth Lab adds new products and partners to mobile personal healthcare offering 2iHealth Lab adds new products and partners to mobile personal healthcare offering 3North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 2North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 3North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 4
... Expand Testing Using Cellular ... Antioxidant Activity Assay, ... with the release of results from a new study,showing Wild ... red grapes and strawberries in an expanded,test using the Cellular ...
... Oct. 8 Vical Incorporated (Nasdaq: VICL ... nonclinical data,demonstrating that the company,s Vaxfectin(R) adjuvant may ... vaccines and,peptide-based cancer vaccines. Alain P. Rolland, Pharm.D., ... present the data today,Wednesday, October 8, at the ...
Cached Medicine Technology:Wild Blueberries Take Top Spot in New Antioxidant Research Study 2Wild Blueberries Take Top Spot in New Antioxidant Research Study 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5
(Date:5/21/2013)... Patients of Dr. Michael Shenk and Dr. Judd Shenk of ... disease and would like permanent tooth replacements now have alternatives ... gum surgery. Gum disease must be treated prior to ... all tooth replacement options. , The Laser Assisted New ... the Food and Drug Administration (FDA) that greatly improves patients’ ...
(Date:5/21/2013)... (PGAs), drugs which lower intraocular pressure, are often the ... their use is not without risks. PGAs have long ... color and other side effects. Now a new study ... lower eyelid drooping and other issues that can interfere ... ONE . , Researchers from the Massachusetts Eye and ...
(Date:5/21/2013)... Dallas, Texas (PRWEB) May 21, 2013 ... growth. Its expanding national presence has required the hiring ... , HealthSmart is pleased to announce that Dawn ... She is serving as the Director of Account Management ... HealthSmart Corporate offices in Irving, Texas. With extensive client ...
(Date:5/21/2013)... AZ (PRWEB) May 21, 2013 ... and inventors who want to develop their ideas ... summer program. , The university is recruiting ... revolutionary new “formation space” that provides early-stage entrepreneurs ... While AREA48 is open to anyone, ASU is ...
(Date:5/21/2013)... May 21, 2013 Phoseon Technology will ... at the 20th Annual IMI European Ink Jet Conference ... market leader, Phoseon continues to invest in product development ... adoption of UV LED curing in printing applications. ... on the market offering both air cooled and water ...
Breaking Medicine News(10 mins):Health News:Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA 2Health News:Glaucoma drug can cause droopy eyelids 2Health News:New Talent Joins the HealthSmart Account Management Team 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4
... 12 As the exclusive official,breaking news service ... 19-22, PR Newswire is featuring profiles of the ... Company: Defibtech, LLC, Booth Number: 16D18-11, ... LLC is a leading innovator in the field ...
... ForHealth Technologies, IntelliFill i.v. robot to ... reduces errors and ... ForHealth Technologies,Inc., a pioneer in medication error reduction and ... its robotic I.V. dose,preparation system, IntelliFill i.v.(TM), by the ...
... BERGEN, N.J., Nov. 12 The Vitamin Shoppe,announced ... Vice President,General Counsel and Corporate Secretary. Mr. Sander ... capacity, Mr. Sander will be responsible for,Legal Affairs, ... "As the Nation,s fastest growing specialty retailer of ...
... First member satisfaction survey shows health improvements, disease ... among valued benefits of plan -, SAN ANTONIO, Nov. ... 91 percent of members of Care Improvement Plus feel,their health ... satisfaction of the plan,s statewide membership. Of those who,feel health ...
... in the November issue of the Springer journal ... has been cut to levels substantially below the cost ... and clinics around the country are likely to discontinue ... to the test and jeopardizing those at risk for ...
... Donostia hospital in representation of Bioef are taking part in ... a portable device that will revolutionise the manner of controlling ... time needed for their detection from the current 24 hours ... to an increase in the number of control points. This ...
Cached Medicine News:Health News:Defibtech, LLC Exhibiting at MEDICA 2008 2Health News:Alegent Health System Automates I.V. Preparation to Enhance Patient Safety 2Health News:The Vitamin Shoppe Names James Sander Vice President, General Counsel and Corporate Secretary 2Health News:Texas Care Improvement Plus Members Overwhelmingly Pleased with Special Needs Plan 2Health News:Osteoporosis care at risk in the United States 2Health News:Design of system that will revolutionize control of influenza epidemics 2
The Storz Protege is an anterior segment unit only....
The Storz Premiere comes as anterior, posterior and anterior/posterior combo. The combo provides the following modes irrigation, irrigation/aspiration, vitrectomy, and illumination....
Compact ultrasonic phacoemulsification system....
... Precisionist workstation is a unique combination ... allowing infinite flexibility for modular hardware ... the demands of changing cataract surgical ... concept in ophthalmic surgical platforms providing ...
Medicine Products: